Recently, the binding of IGFBP-3 to a variety of growth factors was shown to improve the efficacy of anti-cancer precision therapy, counteract numerous mechanisms of tumor resistance, and combat tumor heterogeneity [86]. The gene discussed is IGFBP3; the disease is neoplasm.